To access this element change to forms mode OFF
Grant Award View - GA278325
The development of DMX8.1 as a novel treatment for...
GA ID:
GA278325
Agency:
National Health and Medical Research Council (NHMRC)
Approval Date:
7-Dec-2022
Publish Date:
9-Jan-2023
Category:
Medical Research
Grant Term:
1-Jan-2023 to 31-Dec-2025
Value (AUD):
$915,215.00
(GST inclusive where applicable)
One-off/Ad hoc:
No
Aggregate Grant Award:
No
PBS Program Name:
NHMRC 21/22 1.1 Health and Medical Research
Grant Program:
Development Grants
Grant Activity:
The development of DMX8.1 as a novel treatment for immunotherapy-refractory cancers
Purpose:
Optimal treatment is critical for cancer patient outcome, however, a significant proportion of patients fail to respond and relapse. Using clinically-relevant tumour models, this proposal is aimed at validating the efficacy of a novel drug that can be used either alone or in combination with other therapeutic agents to define the best combination and sequence of treatments to allow immunotherapies to be more effective in more patients.
GO ID:
GO Title:
NHMRC Development Grants 2022 for funding in 2023
Internal Reference ID:
2022/GNT2022693
Selection Process:
Targeted or Restricted Competitive
Confidentiality - Contract:
Yes
Confidentiality Reason(s) - Contract:
Privacy Act 1988
Intellectual property
Intellectual property
Confidentiality - Outputs:
Yes
Confidentiality Reason(s) - Outputs:
Intellectual property
Grant Recipient Details
Recipient Name:
The Council of the Queensland Institute of Medical Research
Recipient ABN:
31 411 813 344
Grant Recipient Location
Suburb:
Herston
Town/City:
Herston
Postcode:
4006
State/Territory:
QLD
Country:
AUSTRALIA
Grant Delivery Location
State/Territory:
QLD, Overseas
Postcode:
Multiple
Country:
AUSTRALIA, UNITED KINGDOM